Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.
单位：[1]Nanjing First Hospital, Nanjing Medical University, Nanjing, China.[2]Guangdong Provincial Peoples Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China.广东省人民医院[3]General Hospital of Tianjin Medical University, Tianjin, China.[4]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.[5]First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.[6]Beijing Anzhen Hospital, Beijing, China.首都医科大学附属安贞医院[7]General Hospital of Northern Theater Command, Shenyang, China.[8]ZhongNan Hospital of Wuhan University, Wuhan, China.[9]Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院[10]The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.[11]Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China
This study aimed to assess the long-term effects of pulmonary artery denervation (PADN) on mortality in patients with pulmonary arterial hypertension (PAH).Between March 2012 and March 2018, a total of 120 patients with PAH, who underwent PADN treatment and were prospectively followed up, were analysed. Patients were classified into World Health Organization (WHO) Functional Class I and II (FC 1-2; n=46) and Functional Class III and IV (FC 3-4; n=74) according to their FC prior to PADN. The primary endpoint was lung transplantation-free mortality until March 2021. The secondary endpoint was a change in the six-minute walk distance (6MWD). During the median of 4.8 years of follow-up, 23 (19.2%) patients died, predominantly from the FC 3-4 group (25.7%), compared to 8.7% in the FC 1-2 group (p=0.034). The mortality rate at one year (2.2% vs 12.2%, p=0.087) and three years (6.5% vs 17.6%, p=0.102) was numerically low in the FC 1-2 group versus the FC 3-4 group, respectively. The median net increase of 6MWD was +29 m in the FC 1-2 group, compared to +60.5 m in the FC 3-4 group (p=0.037).PADN results in significant improvements in survival at long-term follow-up, especially in patients with PAH in FC 3-4. This study was the continuation of the PADN-1 study which was registered at URL: http://www.chictr.trc.com.cn. Unique identifier: chiCTR-ONC-12002085.
基金：
Nanjing Health Bureau
and the National Science Foundation of China (Funding number:
NSFC 91639303 and NSFC 81770441).
语种：
外文
PubmedID：
第一作者：
第一作者单位：[1]Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Nanjing First Hospital, Nanjing Medical University, Nanjing, China.[11]Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China[*1]Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China
推荐引用方式(GB/T 7714)：
Zhang Han,Kan Jing,Zhang Caojing,et al.Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.[J].AsiaIntervention.2022,8(1):58-68.doi:10.4244/AIJ-D-21-00033.
APA：
Zhang Han,Kan Jing,Zhang Caojing,Yang Zhenweng,Gu Heping...&Chen Shao-Liang.(2022).Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class..AsiaIntervention,8,(1)
MLA：
Zhang Han,et al."Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.".AsiaIntervention 8..1(2022):58-68
